Alzprotect: Alzprotect : Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind

(marketscreener.com) Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today that the United States Patent and Trademark Office has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind in the treatment of tauopathies. This...https://www.marketscreener.com/news/latest/Alzprotect-Strengthens-Its-Intellectual-Property-Portfolio-for-Its-First-in-Class-Clinical-Stage-D--31846658/?utm_medium=RSS&utm_content=20201123